Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
15 11월 2018 - 4:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
|
FORM 12b-25
|
SEC FILE NUMBER
0001416172
|
|
NOTIFICATION OF LATE FILING
|
CUSIP NUMBER
65342G104
|
|
(Check one):
|
☐ Form 10-K ☐ Form 20-F ☐ Form
11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form
N-CSR
|
For Period Ended:
September 30, 2018
☐ Transition
Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
For the Transition Period Ended: __________________________________________________
Read Instruction (on back
page) Before Preparing Form. Please Print or Type.
Nothing in this form shall
be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing
checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
NEXEON MEDYSTEMS INC
Full Name of Registrant
Former Name if Applicable
1910
Pacific Avenue, Suite 20000
Address of Principal Executive Office
(Street
and Number)
Dallas,
Texas 75201
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check
box if appropriate)
|
(a)
|
The reason described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense
|
☒
|
(b)
|
The
subject annual report,
semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form
N
-SAR or Form N-CSR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar
day following the prescribed due date; and
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if
applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K,
20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time
period.
|
SEC 1344 (04-09)
|
Persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Nexeon MedSystems Inc. (the “Company”)
is unable to file its quarterly report on Form 10-Q for the quarter ended September 30, 2018 within the prescribed period. The
compilation, dissemination and review of the financial information required to be presented in the Form 10-Q has imposed time constraints
on the Company’s management that have rendered timely filing of the Form 10-Q impractical without undue hardship and expense
to the Company. At this time, the Company expects to file the Form 10-Q no later than the fifth calendar day following the prescribed
due date, as permitted by Rule 12b-25.
(Attach extra Sheets if Needed)
PART IV — OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard
to this notification
|
|
Christopher Miller
|
|
(844)
|
|
919-9990
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section
13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify
report(s).
|
Yes
☒ No ☐
|
(3)
|
Is it anticipated that any significant change in results
of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof ?
|
Yes ☒ No ☐
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot
be made.
Anticipated changes in results of operations
for the quarter ended September 30, 2018 from the prior quarter ended September 30, 2017 are due to the acquisition of Medi-Line,
S.A (“Medi-Line”) and its holding company INGEST, SPRL (“INGEST”) On August 30, 2017.
Reporting in the Company’s financial
statements for the three and nine months ended September 30, 2018 include three and nine months activity, respectively, for INGEST
and Medi-Line compared to the three and nine months ended September 30, 2017 which include one month of activity for INGEST and
Medi-Line.
NEXEON MEDSYSTEMS INC
(Name of Registrant
as Specified in Charter)
has caused this notification
to be signed on its behalf by the undersigned hereunto duly authorized.
Date
|
November 14, 2018
|
|
By
|
/s/ Christopher Miller
|
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized
representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement
is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s
authority to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements
or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
|
GENERAL INSTRUCTIONS
|
1.
|
This form is required by Rule 12b-25 (17 CFR 240.12b-25)
of the General Rules and Regulations under the Securities Exchange Act of 1934.
|
|
2.
|
One signed original and four conformed copies of this form
and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance
with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be
made a matter of public record in the Commission files.
|
|
3.
|
A manually signed copy of the form and amendments thereto
shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
|
|
4.
|
Amendments to the notifications must also be filed on Form
12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended
notification.
|
|
5.
|
Electronic Filers:
This form shall not be used by
electronic filers unable to timely file a report solely due to electronic difficulties. Filers unable to submit reports within
the time period prescribed due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of Regulation
S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation
S-T (§232.13(b) of this chapter).
|
|
6.
|
Interactive data submissions
.
This form shall
not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter).
Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either
Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).
|
Nexeon Medsystems (CE) (USOTC:NXNN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Nexeon Medsystems (CE) (USOTC:NXNN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024